PL3556349T3 - Preparat ciekły do podawania pozajelitowego zawierający związek karbaminianowy - Google Patents
Preparat ciekły do podawania pozajelitowego zawierający związek karbaminianowyInfo
- Publication number
- PL3556349T3 PL3556349T3 PL17880335T PL17880335T PL3556349T3 PL 3556349 T3 PL3556349 T3 PL 3556349T3 PL 17880335 T PL17880335 T PL 17880335T PL 17880335 T PL17880335 T PL 17880335T PL 3556349 T3 PL3556349 T3 PL 3556349T3
- Authority
- PL
- Poland
- Prior art keywords
- nongellite
- carbaminate
- administration
- compound liquid
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000007788 liquid Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160170389 | 2016-12-14 | ||
| EP17880335.9A EP3556349B1 (en) | 2016-12-14 | 2017-12-14 | Parenteral liquid preparation comprising carbamate compound |
| PCT/KR2017/014727 WO2018111000A1 (ko) | 2016-12-14 | 2017-12-14 | 카바메이트 화합물을 포함하는 비경구용 액상 제제 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3556349T3 true PL3556349T3 (pl) | 2022-04-11 |
Family
ID=62559693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17880335T PL3556349T3 (pl) | 2016-12-14 | 2017-12-14 | Preparat ciekły do podawania pozajelitowego zawierający związek karbaminianowy |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US12070447B2 (pl) |
| EP (1) | EP3556349B1 (pl) |
| JP (1) | JP7110196B2 (pl) |
| KR (1) | KR102605030B1 (pl) |
| CN (2) | CN118766839A (pl) |
| AU (1) | AU2017374450B2 (pl) |
| CA (1) | CA3046458A1 (pl) |
| CL (1) | CL2019001617A1 (pl) |
| DK (1) | DK3556349T3 (pl) |
| ES (1) | ES2901427T3 (pl) |
| IL (1) | IL267192B2 (pl) |
| MX (1) | MX390841B (pl) |
| MY (1) | MY200159A (pl) |
| PL (1) | PL3556349T3 (pl) |
| PT (1) | PT3556349T (pl) |
| RU (1) | RU2761041C2 (pl) |
| WO (1) | WO2018111000A1 (pl) |
| ZA (1) | ZA201903748B (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7258901B2 (ja) | 2017-11-14 | 2023-04-17 | エスケー バイオファーマスティカルズ カンパニー リミテッド | 欠神発作又は欠神発作を示すてんかんの予防、軽減又は治療のためのカルバメート化合物の使用 |
| JP7408643B2 (ja) * | 2018-09-21 | 2024-01-05 | エスケー バイオファーマスティカルズ カンパニー リミテッド | カルバメート化合物及びそれを含む製剤の急性ストレス障害又は心的外傷後ストレス障害の予防、軽減又は治療のための使用 |
| CA3113052A1 (en) * | 2018-09-21 | 2020-03-26 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for prevention, alleviation, or treatment of status epilepticus |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| US20100204178A1 (en) * | 2006-10-02 | 2010-08-12 | James Cloyd | Novel parenteral carbamazepine formulation |
| ES2708375T3 (es) * | 2005-09-30 | 2019-04-09 | Lundbeck Pharmaceuticals Llc | Nueva formulación parenteral de carbamazepina |
| ES2378279T3 (es) * | 2006-06-29 | 2012-04-10 | Arigen Pharmaceuticals, Inc. | Agente destinado a ser utilizado para una inyección que comprende antibiótico, y solución para inyección que comprende el agente |
| MX2009011619A (es) * | 2007-04-27 | 2010-01-18 | Cydex Pharmaceuticals Inc | Formulaciones que contienen clopidogrel y eter sulfoalquilico-ciclodextrina y metodos de uso. |
| WO2010150946A1 (en) | 2009-06-22 | 2010-12-29 | Sk Holdings Co., Ltd. | Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester |
| US8404461B2 (en) | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
-
2017
- 2017-12-14 PL PL17880335T patent/PL3556349T3/pl unknown
- 2017-12-14 JP JP2019531627A patent/JP7110196B2/ja active Active
- 2017-12-14 ES ES17880335T patent/ES2901427T3/es active Active
- 2017-12-14 AU AU2017374450A patent/AU2017374450B2/en active Active
- 2017-12-14 RU RU2019121911A patent/RU2761041C2/ru active
- 2017-12-14 PT PT178803359T patent/PT3556349T/pt unknown
- 2017-12-14 MX MX2019006939A patent/MX390841B/es unknown
- 2017-12-14 DK DK17880335.9T patent/DK3556349T3/da active
- 2017-12-14 KR KR1020197018404A patent/KR102605030B1/ko active Active
- 2017-12-14 CN CN202410768574.7A patent/CN118766839A/zh active Pending
- 2017-12-14 WO PCT/KR2017/014727 patent/WO2018111000A1/ko not_active Ceased
- 2017-12-14 US US16/468,756 patent/US12070447B2/en active Active
- 2017-12-14 MY MYPI2019003346A patent/MY200159A/en unknown
- 2017-12-14 CN CN201780077651.2A patent/CN110267647A/zh active Pending
- 2017-12-14 CA CA3046458A patent/CA3046458A1/en active Pending
- 2017-12-14 EP EP17880335.9A patent/EP3556349B1/en active Active
-
2019
- 2019-06-10 IL IL267192A patent/IL267192B2/en unknown
- 2019-06-11 ZA ZA2019/03748A patent/ZA201903748B/en unknown
- 2019-06-12 CL CL2019001617A patent/CL2019001617A1/es unknown
-
2024
- 2024-07-22 US US18/779,456 patent/US20240374568A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX390841B (es) | 2025-03-21 |
| ES2901427T3 (es) | 2022-03-22 |
| ZA201903748B (en) | 2020-12-23 |
| AU2017374450B2 (en) | 2023-05-11 |
| WO2018111000A1 (ko) | 2018-06-21 |
| DK3556349T3 (da) | 2022-01-03 |
| CN118766839A (zh) | 2024-10-15 |
| RU2761041C2 (ru) | 2021-12-02 |
| JP7110196B2 (ja) | 2022-08-01 |
| RU2019121911A3 (pl) | 2021-03-05 |
| MX2019006939A (es) | 2019-09-13 |
| CL2019001617A1 (es) | 2019-08-23 |
| EP3556349A4 (en) | 2020-07-01 |
| JP2020502108A (ja) | 2020-01-23 |
| KR20190087568A (ko) | 2019-07-24 |
| US12070447B2 (en) | 2024-08-27 |
| IL267192A (pl) | 2019-07-31 |
| PT3556349T (pt) | 2021-12-28 |
| RU2019121911A (ru) | 2021-01-15 |
| AU2017374450A1 (en) | 2019-07-04 |
| MY200159A (en) | 2023-12-09 |
| IL267192B1 (en) | 2023-01-01 |
| BR112019011914A2 (pt) | 2019-11-05 |
| CN110267647A (zh) | 2019-09-20 |
| KR102605030B1 (ko) | 2023-11-23 |
| US20190314336A1 (en) | 2019-10-17 |
| US20240374568A1 (en) | 2024-11-14 |
| EP3556349B1 (en) | 2021-11-24 |
| IL267192B2 (en) | 2023-05-01 |
| EP3556349A1 (en) | 2019-10-23 |
| CA3046458A1 (en) | 2018-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281863A (en) | Pharmaceutical compositions comprising meloxicam | |
| SI3529248T1 (sl) | Farmacevtske spojine | |
| DK3474804T4 (da) | Medicinsk forbinding | |
| DK3722274T3 (da) | 2-perfluorbutylpentan til oftalmisk indgivelse | |
| DK3727453T3 (da) | Flydende sammensætning til administration | |
| DK3236943T3 (da) | Sammensætninger til ileo-jejunal lægemiddeladministration | |
| IL262335A (en) | Stable nimopidine parenteral formulation | |
| BR112016026879A2 (pt) | Composição farmacêutica líquida | |
| PT3298027T (pt) | Compostos depsipéptidos antelmínticos | |
| DK3532029T3 (da) | Flydende farmaceutisk sammensætning | |
| DK3237045T3 (da) | Indretning til indgivelse af lægemidler | |
| DK3496551T3 (da) | Flydende allulosesammensætning | |
| PL3518892T3 (pl) | Preparat farmaceutyczny zawierający związek insuliny | |
| DK3145488T3 (da) | Flydende farmaceutiske forbindelse | |
| DK3529240T3 (da) | Farmaceutiske forbindelser | |
| SI4119569T1 (sl) | Konjugirane protismiselne spojine za uporabo v terapiji | |
| PL3093018T3 (pl) | Preparat farmaceutyczny zawierający związki kwasu pirydyloaminooctowego | |
| DK3363428T3 (da) | Perfusionsdoseringsform | |
| LT3464336T (lt) | Junginiai | |
| IL262738B (en) | Intravenous infusion set | |
| EP3437644A4 (en) | MEDICINE | |
| HUE054351T2 (hu) | Vegyületek | |
| DK3597189T3 (da) | Krystallinske forbindelser | |
| EP3527216A4 (en) | Medicine | |
| DK3173071T4 (da) | Maropitantformulering |